Moderna refused to disclose mRNA vaccine technology to China — report
Moderna has been protective of the intellectual property surrounding its vaccine, including being willing to go to court and accusing other companies of patent infringement. Now the most recent update puts a magnifying glass on Moderna’s dealings with China.
Per a report from the Financial Times over the weekend, China asked Moderna to hand over the intellectual property behind its megablockbuster vaccine known as Spikevax. Citing people “familiar with the matter,” the report notes that the mRNA biotech was in negotiations with China in 2020 and 2021 to sell its product in the world’s most populous country.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.